Market access webinar
Navigating the cell and gene therapy market access landscape
Fill in your details to watch this webinar
This webinar explores the cell and gene therapy (CGT) landscape, highlighting key market access challenges, and concludes with considerations for optimizing patient access.
This webinar will provide:
• a summary of the evolving treatment landscape in cell and gene therapies
• an overview of the key challenges to overcome for achieving optimal access, including:
– Demonstrating long-term benefit and managing data collection uncertainties
– Managing complexities around small patient pools
– Affordability of ‘one-off’ high-cost treatments paid over a short duration
– Supporting value differentiation against highly competitive pipelines
• practical considerations on overcoming market access challenges and key barriers for cell and gene therapies
Sanjeev has a number of years of market access experience. He has held senior leadership roles within the pharmaceutical industry and recently led launch excellence activities in cellular therapy covering all aspects from access to operational implementation.
His experience spans translational medicine, health systems, and commercialization in drug development and diagnostics. Sanjeev has a deep interest in cell and gene therapy, companion diagnostics, clinical pathways, real-world data, and cancer systems.
He has expertise across a number of disease areas with a specialism in oncology/hematology.
As the leader of the Market Access Practice at Avalere, Lance Grady devises commercialization strategies focused on value, access, and reimbursement.
With a focus in oncology and autoimmune disease, and over 20 years of experience in policy, access, and reimbursement strategy, he provides practical and meaningful advisory services to healthcare stakeholders.
Lance delivers proven, measurable outcomes by creating integrative and sustainable solutions in functional areas pertaining to drug value and pricing; health plan and payer engagement strategy; benefit design, patient affordability, and access strategy and services; drug-dollar-data flow for medical and pharmacy benefit; oncology pathways; specialty channel strategies; and CMS policy strategy with a focus on coverage, reimbursement, and alternative payment models.
Sudha has 7 years’ experience working across market access consulting, life sciences academic research, and business development, partnering with pharmaceutical and medical device companies in the APAC region.
She has led and contributed to multiple market access projects involving market opportunity assessment, pricing and reimbursement potential evaluation, real-world evidence capabilities mapping, as well as new technology scoping projects.
Her work has spanned multiple therapeutic areas including rare diseases, oncology (with a focus on innovative therapies such as CAR-Ts), vascular disorders, mental health, cardiometabolic as well as infectious diseases in APAC countries.
Ye has several years’ consultancy experience in health technology assessment and market access across Europe, Asia, the Middle East, and Latin America.
At PRMA Consulting she has worked on multiple projects on market access, pricing and reimbursement strategy, market risks and opportunity assessments, evidence generation planning, and cost-effectiveness and budget impact modeling. Her experience spans a range of therapeutic areas, particularly mood disorders, autoimmunology, rare diseases, oncology, and ophthalmology, with an interest focusing on gene therapies.
Duration: 20 minutes.